BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Job Trends

  Horizon Therapeutics Quadruples Space in Maryland to Foster Scientific Innovation

  Horizon Therapeutics’ Bill Rees spoke to BioSpace about the scientific discovery and collaboration potential of its new Rockville, Maryland site, which is expected to open in 2024.

  June 13, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  CRISPR Tx Drug Targeting CD70 Offers Early Hope for Difficult T Cell Lymphomas

  CRISPR Therapeutics shared positive initial data from its Phase I COBALT-LYM trial of CTX130 for cancer which demonstrated safety and efficacy when used to target CD70.

  June 13, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need

  Genmab’s Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.

  June 13, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Amylyx Notches First Regulatory Win for ALS Drug in Canada

  The approval of AMX0035, which will be marketed under the brand name Albrioza, marks the first new ALS drug approved in Canada since 2018.

  June 13, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  The Race is On as Sanofi-GSK Booster Bests Pfizer-BioNTech

  While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.

  June 13, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Inches Ever Closer To COVID-19 Vaccine Approval for Young Children

  Ahead of a scheduled Advisory Committee meeting this week, the FDA released favorable remarks about the Pfizer-BioNTech and Moderna COVID-19 vaccines for children under the age of five.

  June 13, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Novo Nordisk’s Sogroya Shows Promise in Children with GHD

  Initial data from Novo Nordisk’s Phase III trial on Sogroya (somapacitan) to treat growth hormone deficiency (GHD) demonstrated safety and efficacy in prepubertal children.

  June 13, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  Ionis Scores Orphan, Rare Pediatric Disease Designations for Angelman Syndrome Candidate

  ION582 is uniquely formulated using RNA technology to provide relief to patients with Angelman syndrome, a rare disorder for which limited treatment options are available.

  June 13, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Versanis Hopes to Compete with Lilly, Novo in Weight Loss Space

  Versanis Bio’s data reveals the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.

  June 13, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Scientists And Engineers Have Among the Highest Employment Rates, Study Shows

  A new study that looks into employment has found that doctoral recipients enjoy extremely high employment rates, especially in the fields of science and engineering.

  June 13, 2022

   · 

  5 min read

   · 

  Kaley Lefevre